The Cooper Companies, Inc (COO)

Investment Committee Summary

Investment Thesis

At $55.55 (13 October 2026) Cooper trades on roughly 12x forward earnings, broadly in line with the medical-device peer median. The market is pricing a mature mid-single-digit grower whose myopia-management and fertility premium has largely been competed away, with residual GLP-1 anxiety attached. The engine's blend sits beneath the tape rather than above it: the shares are trading cheap to a triangulated fair value of $67.81, a gap of +22%, with the probability-weighted expected value at $69.04 and the twelve-month target set from it at $71.40. The capex-bridge discounted cash flow is lower still, because actual capital spending runs materially above the level the archetype assumes for this business — the model is paying for a build the cash flows have not yet earned back. Roughly two-thirds of modelled outcome variance is driven by the multiple rather than by the business, so the equity is hostage to sentiment more than to execution, while an operating margin near 13% (reported GAAP, TTM to Jul 2026) and net debt of ~$2.3B describe a sound but unexceptional financial profile. The BUY rating follows: no margin of safety, and no clear overvaluation either. The single most damaging risk is the structural scenario — reimbursement pressure, competitive entry and GLP-1-driven procedure erosion together — whose target sits below the 52-week low.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($55.55) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear case does not need a recession. CooperVision's growth premium rests on daily silicone-hydrogel share gains and myopia-management adoption; Alcon, Johnson & Johnson and Bausch + Lomb are all adding daily-lens capacity, and private-label pressure in the channel compresses price before it shows up in volume. The fertility franchise faces a quieter threat: clinic volumes are flattening, and any durable improvement in ovulatory health from GLP-1 adoption shrinks the IVF funnel rather than feeding it. Margins then compress just as the capital build peaks — capital spending running near its recent pace against a slowing top line leaves the model over-built, and net debt of ~$2.3B limits how much of that can be absorbed through repurchases. On trough earnings and a de-rated multiple the equity lands below the 52-week low. The mechanism is competitive and demographic rather than managerial: nobody has to make a mistake for the premium to leak away.

Key Debate

P/E Multiple explains 66% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 12.3× consensus forward EPS, vs the house DCF terminal 14.0×, and a peer median 19.7×. The house DCF sits 11% above spot, so the market is pricing in less than the house case — roughly 1.1pp of revenue CAGR.

Variant perception: the house view is above-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($30.90) to a 'Bull — Re-Rate' bull case ($124); the probability-weighted blend (PWEV $69.04) is +24% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 2% of revenue), trimming the gross PWEV of $70.07 to $69.04 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $30.90). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Hospital-Capex / Utilization Recession (17%, $52.40). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising.
• Base — Procedure Volume + Innovation (35%, $72.70). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns.
• Growth — New-Product Cycle / Penetration (20%, $98.10). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $124). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration.

Valuation Triangulation

Four weighted anchors — an intrinsic dcf, a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat four numbers as four independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $65.53 and 66% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (66% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — explicit-period cash flows with an exit-multiple terminal

A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 14.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $61.84. The terminal value is 72% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (41%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.

Peer benchmarking — relative value

Against its 4 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 19.7x) implies $89.03. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so market sentiment does not set the fair value.

Across all anchors the spread is 40% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)

Tornado — DCF/share swing by driver (widest first)

Company lever — value at the base multiple vs Medical Devices & Equipment multiple (base 15.0x)

Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.

Peer Quality & Weighting

Quality-weighted forward P/E: 21.6× (simple median 19.7×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $51.01–$89.83, centre $67.70 (+22% vs spot); spot sits at the 12th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk = (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' target ÷ price). 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' ($30.90, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. Bull case (Bull — Re-Rate): $124.

Company Overview & Business Model

The Cooper Companies, Inc — HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES. The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.

Company description as supplied by Alpha Vantage; not checked against the company's filings.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 16.7% for the fiscal year ended 2025-10-31; 12.8% TTM to 2026-07-31 (Alpha Vantage INCOME_STATEMENT).

Edge. Narrow moat — A narrow moat — CooperVision's myopia-management/specialty-lens IP and CooperSurgical's fertility installed base give some stickiness but the premium has largely been competed away, so the DCF terminal multiple has no claim above the med-device peer ~15x; if myopia-management share erodes it should compress toward ~13x.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 16.7% for the fiscal year ended 2025-10-31; 12.8% TTM to 2026-07-31 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-10-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 2% of revenue; cash conversion (OCF/NI) 212% — cash-backed.

Competitive Moat

Moat sources:

• FACT: CooperVision myopia-management (MiSight) regulatory clearances and specialty/toric lens IP create modest switching costs for fitted patients
• FACT: CooperSurgical fertility consumables/devices are embedded in IVF clinic workflows (recurring consumable pull-through)
• INFERENCE: duopoly-adjacent lens market (vs J&J Vision, Alcon, Bausch) limits pricing power — premium already competed away per the thesis
• INFERENCE: no evidence of a widening moat — a mid-single-digit grower trading in line with the med-device peer median

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q3): management +0.43 vs analyst floor -0.01 → delta +0.44 (n=29 mgmt / 25 Q&A; 57th pctile across the S&P book, z +0.2).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 917 articles): avg ticker sentiment +0.17 (bullish 25% / bearish 7%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-12-03 (~52d) — Quarterly earnings — est. EPS $1.07 (AV EARNINGS_CALENDAR)
• 2027-02-15 (~126d) — CooperSurgical fertility investor update / capacity expansion (authored)
• 2027-05-20 (~220d) — New-product-cycle margin update (specialty/toric mix) (authored)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +4.5%.

Catalyst Timeline

5 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 1 bullish / 1 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• CooperVision organic revenue growth (constant currency) below 2.0% year-on-year (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Consolidated non-GAAP operating margin below 22.9% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• FY revenue guidance cut below $4.40B (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• CooperSurgical fertility revenue growth below 0% year-on-year (2 consecutive prints). Fertility is the higher-growth pillar of the portfolio; two prints of outright decline is the observable mechanism of the structural scenario (GLP-1 and clinic-volume erosion of the IVF funnel).
• Annual capital expenditure above $0.50B while organic revenue growth runs below 4% (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $55.55; 52-week range $51.01–$89.83; engine rating BUY; house target $71.40 (+29%). (source: Alpha Vantage 2026-10-12, 13 October 2026)
• INFERENCE: Triangulated FV $67.81 (+22% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

60.5/100 (confidence band 46.6–74.5), 64th percentile of 928 covered names (as of 2026-10-12). Weighted composite under config ros-1.21.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 58.3 → 59.2 → 59.5 → 60.7 → 61.1 → 60.9 → 60.8 → 61.1.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $70.07.

Factor Exposures

Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.34, vs QQQ +0.23 (trailing ~1y daily returns).

Rating Bridge

Rating = BUY because:

• Probability-weighted scenario value implies +24% vs spot
• Monte Carlo median implies +18% vs spot
• DCF fair value (exit-multiple terminal) implies +11% vs spot — but this is terminal-value sensitive (exit-multiple $61.84 vs Gordon $73.58, 19% apart), so it carries less weight
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -44% vs spot
• Net: reward/risk of 0.5× supports a Buy — note this is below 1.0×, i.e. the modelled downside exceeds the modelled upside despite the Buy rating.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $4B + PV(terminal) $10B = EV $14B; − net debt $2.3B → equity $12B ÷ diluted shares $0.20B = $61.84/share (exit-multiple terminal).

• Gordon terminal → $73.58/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
• Incremental ROIC on the forecast capex ≈ 11% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: same-sub-industry median fwd P/E → $89.03; EV/Rev → $68.03.

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (19.0); Model op margin ±3pp (18.0); Terminal × ±15% (16.0); Capex intensity ±15% (9.0); WACC ±1pp (6.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 14×, FY+5 revenue $5B. Triangulation leans 41% on DCF, 29% on PWEV, 18% on the Monte Carlo median, 12% on peer-implied value.